911,793 Progyny, Inc. $PGNY Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lessened its stake in Progyny, Inc. (NASDAQ:PGNY) by 35.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,636,371 shares of the company’s stock after selling 911,793 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Progyny were worth $41,220,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Public Employees Retirement System of Ohio purchased a new position in shares of Progyny during the second quarter valued at approximately $29,000. Nykredit A S bought a new stake in Progyny during the second quarter worth $38,000. IFP Advisors Inc raised its position in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after buying an additional 1,549 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in Progyny in the 2nd quarter valued at $65,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Progyny in the 2nd quarter valued at $74,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Up 1.6%

Progyny stock opened at $27.84 on Thursday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The company’s 50 day moving average price is $26.48 and its two-hundred day moving average price is $25.37. The stock has a market cap of $2.14 billion, a P/E ratio of 30.26, a P/E/G ratio of 1.89 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. Progyny’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 1.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PGNY. Canaccord Genuity Group set a $35.00 price objective on Progyny in a research note on Friday, August 7th. Citizens Jmp upped their target price on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. KeyCorp upped their target price on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. BTIG Research increased their target price on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 24th. Finally, Barclays dropped their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.36.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president owned 75,816 shares of the company’s stock, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the transaction, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 9.90% of the company’s stock.

About Progyny

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.